IPHA
$1.34
Innate Pharma S.A.
Recent News
Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy
Innate Pharma (IPHA) said Monday that the US Food and Drug Administration completed a review of its
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Innate Pharma (IPHA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
How the Narrative Around Innate Pharma Is Shifting After Recent Strategic Decisions
Innate Pharma’s consensus analyst price target has recently jumped from €4.34 to €4.93. This marks a significant shift in expectations for the stock. This change comes amid a period of strategic transition, with analysts debating the company’s new priorities and ongoing risks. Readers interested in how analyst sentiment may keep evolving should continue following updates to stay ahead of future narrative shifts. What Wall Street Has Been Saying 🐂 Bullish Takeaways Several analysts highlight...
Target initiated, Nike upgraded: Wall Street's top analyst calls
Target initiated, Nike upgraded: Wall Street's top analyst calls
Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ...
Innate Pharma SA (IPHA) reports strong cash position and progress in clinical assets, while navigating organizational restructuring and competitive pressures.